Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorders with rituximab using a maintenance treatment regimen and close CD19 B cell monitoring. A six-year follow-up
Neuromyelitis optinca (NMO) represents a serious demyelinating disease of the CNS The disease selectively attacks the spinal cord and optic nerve. Early differential diagnosis from multiple sclerosis is of vital importance Five patients Rituximab treatment of NMO & NMOSD patients improves disability and relapse rate without significant adverse effects.